1. Аndreeva T.А., Zorenko V.Yu., Davydkin I.L.et al. Efficacy and safety of Oktofactor in the treatment of patients with severe and moderate haemophilia A (results of phase II and III clinical trial, part 2). Voprosy Gematologii/Onkologii i Immunopatologii v Pediatrii, 2013, vol. 12, no. 4, pp. 31–37. (In Russ.)
2. Galstyan G.M., Polevodova O.А., Terekhova I.V. et al. Use of thromboelastography, throbin generation test and clotting tests to assess efficacy of homeostatic therapy with recombinant activated factor VII in the patients with the inhibitory form of hemophilia, Ros. Journal Detskoy Gematologii i Onkologii, 2017, no. 4, pp. 33–38. (In Russ.)
3. Gladysheva V.G. Vliyanie aktivirovannogo faktora VII na gemostaticheskiy potentsial pri massivnykh refrakternykh krovotecheniyakh u kardiokhirurgicheskikh bolnykh. Avtoref. diss. kand. med. nauk. [Impact of recombinant activated factor VII on homeostatic potential in case of massive refractory bleeding in the patients undergoing cardiac surgery. Cand. Diss. Synopsis]. Moscow, 2006.
4. Davydkin I.L., Аndreeva T.А., Zorenko V.Yu. et al. Efficacy and safety of Oktofactor in the preventive treatment of patients with severe and moderate haemophilia A (results of phase II and III clinical trial, part 1). Voprosy Gematologii/Onkologii i Immunopatologii v Pediatrii, 2013, vol. 12, no. 3, pp. 29–37. (In Russ.)
5. Dementieva I.I., Gladysheva V.G., Morozov Yu.А. The impact of the drug of Novo Seven on the volume of hemotransfusions in the patients undergoing cardiac surgery and suffering from increased hemophilia of non-surgical genesis. Vestnik Intensivnoy Terapii, 2005, no. 3, pp. 59–61. (In Russ.)